Labroots

AcroMetrix BCR-ABL External Molecular Panel: An Accurate Testing Method for Chronic Myeloid Leukemia

To support the validation and verification of new assays and to challenge the existing assays in oncology testing, Thermo Fisher Scientific launches Thermo Scientific Acrometrix BCR-ABL Panel. The ...
ascopubs.org

BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia.

Expression of CD74 by AML blasts and cell lines, and enhanced in vitro cytotoxicity of anti-CD74 antibody after interferon-gamma (IFN-γ) treatment. Background: Current NCCN guidelines recommend ...
Business Insider

Cepheid Receives FDA Clearance for Xpert® BCR-ABL Ultra Test

SUNNYVALE, Calif., Oct. 2, 2019 /PRNewswire/ -- Cepheid today announced that it has received clearance from the U.S. Food and Drug Administration for Xpert BCR-ABL Ultra for monitoring disease burden ...
Business Insider

Thermo Fisher Scientific Launches New External Molecular Control Panel for the Analytical Evaluation of BCR-ABL Test Methods

FREMONT, Calif., Oct. 17, 2019 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific Acrometrix BCR-ABL Panel, its ...
FierceBiotech

MolecularMD and ARIAD Announce Voluntary Withdrawal Of MolecularMD’s Premarket Approval Application For BCR-ABL T315I Mutation Test

ARIAD Pharmaceuticals, Inc.Kendra Adams, 617-503-7028orLiza Heapes, 617-621-2315orKatherine Clock, 503-459-4974 and (NASDAQ: ARIA) today announced that MolecularMD has voluntarily withdrawn its ...
FiercePharma

Medco Partners With MolecularMD on Personalized Medicine Program for Chronic Myeloid Leukemia

FRANKLIN LAKES, N.J. and PORTLAND, Ore., June 2, 2011 /PRNewswire/ -- Medco Health Solutions, Inc. (NYSE: MHS) and MolecularMD Corp. today announce the launch of a personalized medicine program for ...
ascopubs.org

Flow cytometric bead assay of BCR-ABL fusion proteins in leukemia patients: An Indian experience.

Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib. Background: The BCR-ABL fusion gene results from the translocation t(9;22). It is the hallmark of chronic ...
Nature

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic ...

Complete remission (CR) rates exceed 90% when imatinib is used as frontline therapy for newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia ...
GEN

Asuragen and Novartis to Facilitate Standardization of BCR-ABL1 RT-qPCR Results

Asuragen will develop international scale calibrators and software reporting tools. Asuragen inked an exclusive agreement with Novartis to develop international scale (IS) calibrators and laboratory ...
AHA/ASA Journals

Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design

BACKGROUND: BCR-ABL tyrosine kinase inhibitors (TKIs) have been increasingly linked to pulmonary arterial hypertension (PAH) since 2009, although supporting evidence is limited. Our objective was to ...
Nature

BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the t(9;22) translocation coding for the chimeric protein p210 BCR-ABL. The tumor suppressor phosphatase and tensin ...